HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brar, B. K. Articles by Latchman, D. S. Search for Related Content PubMed PubMed Citation Articles by Brar, B. K. Articles by Latchman, D. S. Social Bookmarking                      What's this?

J Biol Chem, Vol. 275, Issue 12, 8508-8514, March 24, 2000

Urocortin Protects against Ischemic and Reperfusion Injury via a MAPK-dependent Pathway^*

Bhawanjit K. Brar^§, Anna K. Jonassen^¶, Anastasis Stephanou, Giorgia Santilli^**, Julia Railson, Richard A. Knight^**, Derek M. Yellon^¶, and David S. Latchman

From the  Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, the ^¶ Hatter Institute of Cardiology, University College London Hospitals and Medical School, London WC1E 6DB, and the ^** Department of Cystic Fibrosis, National Heart and Lung Institute, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, United Kingdom

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Urocortin (UCN) is a peptide related to hypothalamic corticotrophin-releasing hormone and binds with high affinity to corticotrophin-releasing hormone receptor-2, which is expressed in the heart. In this study, we report that UCN prevented cell death when administered to primary cardiac myocyte cultures both prior to simulated hypoxia/ischemia and at the point of reoxygenation after simulated hypoxia/ischemia. UCN-mediated cell survival was measured by trypan blue exclusion, 3'-OH end labeling of DNA (TUNEL), annexin V, and fluorescence-activated cell sorting. To explore the mechanisms that could be responsible for this effect, we investigated the involvement of MAPK-dependent pathways. UCN caused rapid phosphorylation of ERK1/2-p42/44, and PD98059, which blocks the MEK1-ERK1/2-p42/44 cascade, also inhibited the survival-promoting effect of UCN. Most important, UCN reduced damage in isolated rat hearts ex vivo subjected to regional ischemia/reperfusion, with the protective effect being observed when UCN was given either prior to ischemia or at the time of reperfusion after ischemia. This suggests a novel function of UCN as a cardioprotective agent that could act when given after ischemia, at reperfusion.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Urocortin (UCN)¹ is a peptide related to the hypothalamic hormone corticotrophin-releasing factor (CRF), the central mediator of the hypothalamic-pituitary-adrenal axis and stress response in mammals (1-3). UCN and CRF share 45% homology at the amino acid level, and both are synthesized as precursors, which are subsequently processed to the mature biologically active peptides (in the case of UCN, a 40-amino acid molecule) (4, 5). Although UCN was originally identified in restricted areas of the brain, it has also been found in the placenta, lymphocytes, and heart (6-9).

The CRF family of peptides bind two types of CRF receptors, CRF-R1 and CRF-R2. CRF-R2 exists in three alternative splice variant forms, CRF-R2, CRF-R2, and CRF-R2 (10-12); and CRF-R2 binds UCN with a higher affinity than CRF both in ligand binding studies (4) and as shown by the effects of ligand on intracellular cAMP (13). In contrast, the R1 receptors show little ligand selectivity for UCN versus CRF. R2 receptors are the only type of CRF receptor found in the heart: the  form in man (14) and the  form in the rat (15). The CRF family of peptides have been shown to stimulate adenylate cyclase activity in cardiac myocytes (16), and changes in CRF-R2 expression have been reported in the hearts of spontaneously hypertensive rats (17).

The coincident expression of CRF-R2 receptors with their preferred UCN ligand in the heart suggests that UCN may have physiological cardiac properties. Indeed UCN, but not CRF, induces a dose-dependent increase in heart rate, cardiac output, and coronary blood flow (18). Moreover, cardiac CRF-R2 expression is modulated by endotoxin, a potent inducer of cardiovascular dysregulation, further suggesting a possible link between UCN and the cardiovascular response to stress (19). Indeed, in previous studies, we have shown that UCN mRNA expression increases in cardiac cells exposed to thermal and simulated hypoxic/ischemic injury stress in vitro (9) and that endogenous UCN peptide protects cardiac myocytes from cell death when administered prior to the stress (20).

A number of studies have implicated the mitogen-activated protein kinase (MAPK) pathway as a survival pathway in both cardiac cells (21-23) and other cell types (24-29). The extracellular signal-related kinases (ERKs), belonging to one subfamily of MAPKs, are composed of 42- and 44-kDa kinases named p42 ERK and p44 ERK, respectively. Phosphorylation and activation of p42 ERK and p44 ERK are mediated by the MAPKs MEK1 and MEK2.

CRF has been shown to activate ERK1/2-p42/44 in Chinese hamster ovary cell lines transfected with CRF-R1 and CRF-R2 (30). Moreover, the cardioprotective effects of cardiotrophin-1 (CT-1) are mediated through gp130 receptor activation of the MEK1/2-ERK1/2-p42/44 signaling cascade, one consequence of which is increased expression of the cardioprotective hsp70 and hsp90 proteins (31).

In this report, we have extended our studies on the cardioprotective properties of UCN in primary cultures of neonatal rat cardiac myocytes exposed to simulated ischemia/reoxygenation in vitro and show that UCN is also protective in isolated perfused rat hearts ex vivo. In both in vitro and ex vivo models, we show for the first time that this cardioprotective effect of UCN is retained when addition of UCN is delayed until after the simulated hypoxia/ischemia and is given during the reoxygenation/reperfusion. We also show that the protective effects involve activation of the MEK1/2-ERK1/2-p42/44 signaling pathway.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Antibodies and Reagents-- Anti-active MAPK polyclonal antibody and rabbit anti-ERK1/2-p42/44 antibody were obtained from Promega, as were anti-active p38 MAPK polyclonal antibody and rabbit anti-active JNK polyclonal antibody. Anti-actin goat polyclonal antibody was supplied by Insight Biotechnology. Mouse monoclonal antibody to desmin was obtained from Sigma (Dorset, United Kingdom). Secondary antibodies used were horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG and anti-rabbit IgG, which were obtained from Dako A/s (Denmark House, Cambridge, U.K.). For Western blot analysis, all primary antibodies were used at a dilution of 1:1000. Secondary antibodies were used at a dilution of 1:2000.

Recombinant rat UCN peptide was obtained from Sigma. In all experiments, UCN was used at a concentration of 10⁸ M. The MEK1/2 inhibitor PD98059 was purchased from New England Biolabs Inc. (Beverly, MA) and has been shown to act as a highly selective inhibitor of MEK1 activation and the MAPK ERK1/2-p42/44 cascade (32).

Reagents for assessing apoptotic nuclei by end labeling of DNA 3'-OH ends with fluorescein isothiocyanate (FITC)-conjugated 2'-deoxyuridine 5'-triphosphate and terminal transferase were purchased from Roche Molecular Biochemicals. FITC-annexin V conjugate and 0.4% (v/v) trypan blue were purchased from Sigma.

Dulbecco's modified Eagle's medium, penicillin/streptomycin, Versene, L-glutamine, pancreatin, trypsin/EDTA solution, and fetal calf serum were purchased from Life Technologies, Inc. (Middlesex, United Kingdom). Collagenase type II was obtained from Worthington. A sterile tissue culture apparatus was obtained from Falcon Marathon Lab Supplies (London). All tissue culture incubations, experiments, and manipulations were performed using sterile techniques in a laminar air flow cabinet. An enhanced chemiluminescence kit (ECL) was obtained from Amersham Pharmacia Biotech (Buckinghamshire, United Kingdom). 5% CO₂, 0% O₂, and balance gas N₂ were obtained from BOC Ltd. Specialty Gases (London). Hybond C nitrocellulose membrane was obtained from Amersham Pharmacia Biotech. All other chemicals and reagents were obtained from Sigma, if not stated otherwise.

Preparation of Neonatal Rat Cardiac Myocyte Cultures-- Ventricular myocytes were isolated from the hearts of neonatal rats (Harlan Sprague-Dawley) <2 days old and were cultured as described previously (33)_. This cardiac myocyte-isolating system yields cell cultures that are >95% myocytes as determined by indirect staining with a mouse monoclonal antibody to desmin. Cardiac myocyte cell suspension was transferred to six-well (3-cm diameter) gelatin-coated plates at a density of 10⁵ cells/well for protein extraction experiments. Cell were plated on 24-well (1-cm diameter) plates for experiments involving assessment of cell death. After 24 h following plating, the cell medium was replenished with Dulbecco's modified Eagle's medium supplemented with fetal calf serum at 1% (v/v) for an additional 24 h before experimentation (hereafter referred to as growth medium). Within 2 days of preparation, a confluent monolayer of spontaneously beating myocytes was formed.

Activation of ERK1/2-p42/44 by UCN-- Cardiac myocytes were cultured in serum-free medium for 24 h at 37 °C in a humidified atmosphere of 5% CO₂ and 21% O₂ (normoxic environment) and treated with UCN for 10 min and 1, 6, and 24 h in six-well culture dishes. Cells were harvested immediately in 200 µl of ice-cold lysis buffer containing 0.1% (v/v) 2-mercaptoethanol, 0.01% (v/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 mM Tris (pH 7.4), 0.2 mM sodium vanadate, and 0.2 mM phenylmethylsulfonyl fluoride. An aliquot of cell lysate was retained for protein content determination (Bio-Rad). Cellular proteins were resuspended in an equal volume of 2× sample treatment buffer (100 mM Tris (pH 6.8), 200 mM dithiothreitol, 4% (w/v) SDS, 0.2% (w/v) bromphenol blue, and 20% (w/v) glycerol). The samples were boiled for 3 min, and proteins were electrophoresed on a 12% SDS-polyacrylamide gel, subsequently transferred onto Hybond C nitrocellulose membranes, and then probed for 2 h at room temperature using an antibody that detects phosphorylated ERK1/2-p42/44. The membranes were washed in PBS and 0.05% (v/v) Tween and incubated with a peroxidase-conjugated antibody. Immunoreactive bands were visualized by ECL. The relative protein levels were determined using densitometry (Bio-Rad), normalizing to the actin band on a duplicate Coomassie Brilliant Blue R-250 (BDH)-stained gel, and probing the membranes with anti-actin antibody.

Exposure of Cardiac Myocytes to Lethal Simulated Hypoxia/Ischemia-- The growth medium of untreated cells was replaced with 1 ml of modified Esumi ischemic buffer. This buffer has a high potassium content and a low acidic pH and hence mimics the conditions of cells within the heart when exposed to oxygen deprivation. It contains 137 mM NaCl, 12 mM KCl, 0.49 mM MgCl₂, 0.9 mM CaCl·2H₂O, 4 mM HEPES, 10 mM deoxyglucose, and 20 mM sodium lactate (pH 6.2) (34). For lethal simulated hypoxic/ischemic treatment, cells were incubated in the hypoxic/ischemic chamber at 37 °C for 6 h in a humidified atmosphere of 5% CO₂, 0% O₂, balance gas N₂ at a pressure of 4 pounds/inch³. Untreated cells were cultured in Esumi control buffer in a humidified atmosphere of 5% CO₂ and 21% O₂ at 37 °C for 6 h as internal controls for this experiment. Modified Esumi control buffer consists of 137 mM NaCl, 3.8 mM KCl, 0.49 mM MgCl₂, 0.9 mM CaCl·2H₂O, 4 mM HEPES, and 10 mM glucose (pH 7.4).

Assessing Cell Death-- Ischemic and reperfusion injury is accounted for by both apoptosis and necrosis (35-37); therefore, to assess both forms of cell death and to obtain a complete understanding of cell survival, it is necessary to use a number of cell death-assessing techniques: trypan blue exclusion (assesses total cell death) and TUNEL, annexin V, and FACS (assess apoptotic death). To assess the quality of cardiac myocytes prior to treatments, cell injury was measured under normoxic conditions. Triphenyltetrazolium chloride staining of isolated rat hearts subjected to regional ischemia assesses infarct size.

Treatment of Cardiac Myocytes with UCN Prior to Ischemic Injury-- Normal growth medium was replaced with serum-free medium for 24 h. UCN was added to the cardiac myocytes immediately and 30 min and 1, 2, and 24 h prior to the lethal simulated hypoxic/ischemic insult. Subsequent to this injury, cell survival was assessed by trypan blue exclusion. The MEK1 inhibitor PD98059 was incubated with the cardiac myocytes in serum-free medium 10 min prior to a 30-min or 24-h incubation of UCN in a normoxic environment. Subsequently, the cells were exposed to a 6-h lethal simulated hypoxic/ischemic insult, and cell injury was assessed by the end labeling of DNA 3'-OH ends with FITC-dUTP, trypan blue exclusion, and FACS analysis for the 24-h UCN incubation period. For annexin V labeling, cells were exposed to only a 2-h ischemic insult as annexin V binds to phosphatidylserine residues that move from the inner membrane to the outer cell membrane during the initial stage of apoptosis.

Trypan Blue Exclusion-- The cells were harvested as described previously (39). Following the addition of an equal volume of 0.4% trypan blue in PBS, the percentage of blue cells/total cells was counted by scoring 250 cells, three times per well, using a hemocytometer.

TUNEL-- Apoptotic nuclei were assessed by the end labeling of DNA 3'-OH ends with FITC-dUTP using a modification of the TUNEL method as described previously (38, 39). TUNEL-positive cells were then imaged by fluorescent microscopy. The percentage of apoptotic nuclei is expressed as a percentage of total nuclei from scoring 250 cells, three times per well.

FACS Analysis-- Cells were incubated with and without UCN in the presence and absence of PD98059 for 24 h prior to exposure to lethal simulated hypoxia/ischemia. Apoptosis and cell death were evaluated by FACS as described previously (n = 3 for each treatment) (31, 40). Briefly, 1 × 10⁶ cells were pelleted by centrifugation at 1200 rpm for 5 min and resuspended in 500 µl of methanol/acetone (4:1) overnight at 4 °C. The cells were then pelleted and resuspended in 50 µl of RNase (20 µg/ml) for 15 min at 37 °C. Subsequent to this incubation period, 100 µl of propidium iodide (40 µg/ml) was added to the cells, which were then incubated in the dark for 20 min at 37 °C. DNA fluorescence was measured using a FACScan (Becton-Dickinson). Nuclei were gated according to fluorescence. The M1 gate detects cells undergoing apoptosis/cell death. The M2 gate detects live cells, i.e. cells in G₁.

Annexin V Labeling-- Cells were incubated, as before, in serum-free medium for 24 h and cultured for 10 min with PD98059 prior to a 30-min or 24-h incubation with UCN. The cells were then exposed to a 2-h ischemic insult and labeled as described previously (39, 41). Briefly, the ischemic buffer was removed, and the cells were washed with PBS. To each of the wells was added 10 µl of FITC-conjugated human annexin V (10 µg/ml) in 90 µl of binding buffer concentrate (HEPES-buffered saline solution supplemented with 25 mM CaCl₂). The cells were incubated at room temperature in the dark for 1 h on a swirling base. The annexin V label was removed, and the cells were carefully washed twice with PBS. Following fixing with 1% (v/v) paraformaldehyde for 30 min at 25 °C, the cells were washed three times with PBS. Annexin V-positive cells are expressed as a percentage of total cells (observed under phase). A minimum of 250 cells were scored, three times per well.

Measurement of Cardioprotective Effects of UCN in Reoxygenation after Simulated Hypoxia/Ischemia-- To investigate the downstream signaling pathways that mediate UCN cardioprotection in reoxygenation injury, the ischemic buffer was removed from the cardiac myocytes at the point of reoxygenation and replaced with 1 ml of serum-free medium with and without the addition of UCN and PD98059 for 2 h. PD98059 was added to the cardiac cells 10 min prior to the addition of UCN. Following a 2-h reoxygenation period, the cardiac myocytes were assessed for cell survival by trypan blue exclusion, TUNEL, and annexin V labeling as described above.

Isolated Rat Heart Preparation (Langendorff Perfusion)-- Twenty-three male Wistar rats (250-350 g) fed a standard diet were heparinized (200 IU) and anesthetized intraperitoneally with sodium pentobarbital (50 mg/kg). The hearts were excised, placed in ice-cold Krebs-Henseleit buffer, and rapidly mounted on the aortic cannula of a Langendorff perfusion system. Perfusion was established within 30 s after thoractomy. The Krebs-Henseleit buffer (pH 7.4, 95% O₂ and 5% CO₂) contained 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 1.8 mM CaCl·2H₂O, 25.2 mM NaHCO₃, and 11 mM glucose. Perfusion pressure was maintained at 100 cm H₂O, and the myocardial temperature was kept constant at 37 °C. A water-filled latex balloon, connected to a hydrostatic pressure transducer (P23XL, Viggo-Spectramed) and coupled to a recorder (Multitrace 2, Lectromed), was inserted into the left ventricle through an incision in the left atrium and inflated to set an end diastolic pressure of 5-10 mm Hg. Coronary flow was measured by timed collection of effluent over 1 min at each sampling point. A 3-0 silk suture was passed around the main branch of the left coronary artery, and the ends were threaded through a small vinyl tube to form a snare. Regional ischemia was achieved by pulling the snare and confirmed by a substantial fall in both left ventricular developed pressure and coronary flow. All hearts underwent 20 min of stabilization before being subjected to 35 min of regional ischemia and 2 h of reperfusion. Base-line values for functional parameters were obtained after 10 min of perfusion. Three groups were included in the study. The first group served as a control (n = 8); the second group was treated with 10⁸ M UCN (n = 7) 30 min prior to ischemia; and the third group received UCN for 30 min from the onset of reperfusion (n = 8). At the end of each experiment, the silk suture was reoccluded, and a 0.5% suspension of zinc-cadmium sulfide fluorescent particles (1-10 µm in diameter; Duke Scientific Corp., Palo Alto, CA) was infused into the perfusate to mark the risk zone as non-fluorescent tissue. The hearts were then frozen and cut into 2-mm thick slices parallel to the atrioventricular groove. The slices were thawed and incubated with 1% triphenyltetrazolium chloride in phosphate buffer (pH 7.4) at 37 °C for 20 min and fixed in 10% Formalin to enhance the contrast of the stain. Slices were then compressed to a uniform 2-mm thickness by placing them between two glass plates separated by a 2.0-mm spacer. The area of the left ventricle, the infarcted area (triphenyltetrazolium chloride stain-negative), and the risk zone (non-fluorescent under UV light) were traced onto acetate transparency using a computerized planimetry program (Summa Sketch II, Summa Graphics, Seymour, CT). The infarct size and the risk zone areas were calculated for each heart slice and the product. Infarct size was expressed as a percentage of the risk zone. These measurements were performed in a blinded fashion. Heart rate, coronary blood flow, and left ventricular developed pressure were measured at 10-min intervals throughout the experiments.

Statistics-- Data for in vitro experiments are expressed as means ± S.D. Single-factor one-way analysis of variance (ANOVA) was performed for each group of treatments, and significance was assumed when the p value was <0.05. Differences among means were compared within the treatment groups using Student's t test. The experiments were repeated at least three times for each experiment as stated in the legends; each n value corresponds to the mean of three random fields/well of cells with a minimum of 250 cells scored per view. The n value for each experiment is stated under "Results." Infarct size data were tested for group differences by ANOVA combined with Tukey's post hoc test. Comparisons of cardiac flow, heart rate, and left ventricular developed pressure were performed with repeated measures of ANOVA. p values <0.05, <0.01, <0.005 were considered significant.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Cardioprotective Effects of UCN Administered 0 and 30 min and 1, 2, and 24 h before Lethal Simulated Hypoxic/Ischemic Injury-- UCN was added to the normal growth medium of cardiac myocytes 0 and 30 min and 1, 2, and 24 h prior to lethal simulated hypoxic/ischemic injury, and cell death was assessed by trypan blue exclusion. The percentage of dead cells in cultures incubated in a normoxic environment was 16.9% (n = 6). Cardioprotection was not detected when UCN was added immediately and removed immediately from the cells, as the percentage of cell death was 60.8% (n = 8) compared with 65.5% (n = 8) of cell death measured in ischemic untreated cells. However, the percentage of cell survival increased when UCN was incubated for the 30-min time period and for longer periods. Cell death decreased from 65.5 to 42.5% (n = 6), 44.4% (n = 6), 42.1% (n = 10), and 47.6% (n = 6) for pretreatment times of 30 min (p < 0.03), 1 h (p < 0.002), 2 h (p < 0.0001), and 24 h (p < 0.001), respectively. No significant increase in cell survival was measured comparing the 30-min and 24-h pretreatments with UCN (Fig. 1). Hence, a 30-min pretreatment with UCN is sufficient for its protective effect.

View larger version (60K): [in this window] [in a new window]   Fig. 1.   Cardioprotective effects of UCN administered before lethal simulated hypoxic/ischemic injury. UCN was added to the normal growth medium of cardiac myocytes 0 and 30 min and 1, 2, and 24 h prior to lethal simulated hypoxic/ischemic injury, and cell death was assessed by trypan blue exclusion. The percentage of dead cells in cultures incubated in a normoxic environment was 16.9% (n = 6). Single-factor ANOVA was performed on the group of treatments that showed highly significant differences (p value = 2.42 × 109). Cell death decreased from 65.5 to 42.5, 44.4, 42.1, and 47.6% for pretreatment times of 30 min (*, p < 0.03), 1 h (**, p < 0.002), 2 h (***, p < 0.0001), and 24 h (**, p < 0.001), respectively. NT, no treatment.

Phosphorylation of ERK1/2 by UCN-- The rapid protective effect of UCN led us to investigate the signaling pathways that it activates and that may reduce its protective effect. CRF has been shown to activate the MEK1-ERK1/2-p42/44 signaling cascade in Chinese hamster ovary cells overexpressing CRF-R1 and CRF-R2 (30). Activation of this signaling pathway mediates the anti-apoptotic effect of CT-1, indicating that it can be protective (21). To study the effects of UCN on ERK1/2 phosphorylation, cardiac myocytes were serum-starved for 24 h and treated with UCN for 10 min and 1, 6, and 24 h. Untreated and UCN-treated cells were harvested, and total cellular proteins were subjected to SDS-polyacrylamide gel electrophoresis and Western blot analysis (see "Materials and Methods") using a antibody specific for phosphorylated ERK1 and ERK2 (p42/44), which migrate at molecular masses of 42 and 44 kDa, respectively. ERK1 and ERK2 (p42/44) were rapidly phosphorylated within 10 min and remained phosphorylated at 1 and 6 h; however, at 24 h, phosphorylated enzyme returned to basal levels (Fig. 2). The phosphorylated levels of ERK1/p42 appear to be greater than those of ERK2/p44 following UCN treatment. No increased phosphorylation of JNK and p38 MAPK was detected after UCN treatment (data not shown). The levels of actin protein were also constant. To our knowledge, this is the first report that UCN activates the MAPK ERK1/2-p42/44 signaling cascade, as has previously been demonstrated for CRF.

View larger version (31K): [in this window] [in a new window]   Fig. 2.   Phosphorylation of ERK1/2-p42/44 by UCN. Cardiac myocytes were serum-starved for 24 h and treated with UCN for 10 min (m) and 1, 6, and 24 h. Cells with no treatment (NT) and UCN-treated cells were harvested, and total cellular proteins were subjected to SDS-polyacrylamide gel electrophoresis and Western blot analysis using an antibody specific for phosphorylated ERK1 and ERK2 (p42/44), which migrate at molecular masses of 42 and 44 kDa. ERK1 and ERK2 were rapidly phosphorylated within 10 min and remained phosphorylated for 6 h; however, at 24 h, phosphorylated enzyme returned to basal levels.

UCN Protection Is Abolished by the MEK1 Inhibitor PD98059-- MEK1 and MEK2 are upstream activators of the p42/44 MAPKs whose activity is inhibited by PD98059 (32). Cardiac myocytes were pretreated for 10 min with PD98059 and cultured with UCN for 30 min and 24 h prior to exposure to lethal simulated hypoxia/ischemia. Cell death was assessed by trypan blue exclusion (Table I). A 30-min pretreatment with UCN prior to ischemia reduced cell death from 75.65% (n = 6) to 45.66% (n = 6; p < 0.016); and UCN cardioprotection was inhibited by pretreatment with PD98059, as cell death increased to 69.25% (n = 6; p < 0.013). The 24-h pretreatment with UCN prior to ischemia reduced cell death from 62.22% (n = 12) to 47.43% (n = 11; p < 0.0001); and UCN cardioprotection was inhibited by pretreatment with PD98059, as cell death increased to 62.55% (n = 11; p < 0.00004). PD98059 administered on its own had no effect on hypoxia/ischemia-induced cell death in both 30-min and 24-h pretreatment experiments, as the percentages of cell death were 64.4 and 62.45%, respectively. Hence, UCN protection against simulated hypoxia/ischemia-induced death is inhibited by the MEK1 inhibitor.

UCN-mediated Cardioprotection Measured by Annexin V, TUNEL, and FACS-- Cell injury was assessed using marker techniques for apoptosis such as annexin V, TUNEL, and FACS analysis. The percentages of dead cells measured by TUNEL, annexin V, and FACS in a normoxic environment prior to the experiment were 10.48% (n = 7), 5.7% (n = 5), and 24.98% (n = 3), respectively. The variation in cell death under normoxic conditions using the different techniques may be accounted for by their different sensitivity and detection of specific markers in the cell death pathway. Since both TUNEL and FACS assess DNA cleavage, it is possible that preparation of cells for FACS may cause some cell damage. However, as seen for trypan blue exclusion, the 30-min pretreatment with UCN produced a cardioprotective effect as observed using annexin V labeling and TUNEL (Table I). Cell injury, as measured by annexin V labeling, was reduced from 44.99% (n = 6) in untreated cells to 29.54% (n = 6; p = 0.04) in UCN-treated cells. UCN-mediated cardioprotection was inhibited by pretreatment with PD98059 prior to UCN, as cell injury increased to 37.60% (n = 6). Cell injury, as measured by TUNEL, was reduced from 37.2% (n = 6) in untreated cells to 30.66% (n = 6) in UCN-treated cells. UCN-mediated cardioprotection was inhibited by pretreatment with PD98059 prior to UCN, as cell injury increased to 39.0% (n = 6).

FACS analysis was performed on untreated cardiac cells and those treated with UCN for 24 h with and without PD98059. Lethal simulated hypoxia/ischemia resulted in 94.76% cell injury/death (M1 gate), which accounts for cells undergoing apoptosis. Incubation of PD98059 alone had no effect on cell survival when administered during the stress. The addition of UCN resulted in a decrease in cell death to 56.34% (p < 0.001), and PD98059 partially abrogated the UCN-mediated cell survival effect to increase cell death to 75.56% (p < 0.041). Hence, UCN activates MEK1, which results in the serine/threonine phosphorylation of factors that mediate the survival effect of UCN.

UCN Protects Cardiac Myocytes from Reoxygenation Injury, and This Effect Is Partially Inhibited by PD98059-- To assess whether UCN retains cardioprotective effects when added after a period of simulated hypoxia/ischemia, UCN was added to the cardiac myocytes at the point of reoxygenation (Table II). Cell death was measured in untreated cells exposed to ischemic reoxygenation by trypan blue exclusion, TUNEL, and annexin V. UCN protected the cardiac cells during reoxygenation when cell death was assessed by trypan blue exclusion (n = 8; p < 0.00025), TUNEL (n = 8; p < 0.0017), and annexin V (n = 6; p < 0.004) compared with untreated cells exposed to ischemic reoxygenation. To investigate whether UCN protection at reoxygenation was mediated by the MEK1-ERK1/2-p42/44 signaling cascade, PD98059 was administered for 10 min prior to the addition of UCN. The cardioprotective effect of UCN was inhibited by PD98059 when cell death was assessed by trypan blue exclusion (n = 8; p < 0.00008) and annexin V (n = 7; p < 0.00015). PD98059 alone had no effect on cell injury during reoxygenation. An inhibitory effect of PD98059 on UCN-mediated protection in simulated ischemic/hypoxic injury was also observed using TUNEL.

UCN Reduces Infarct Size of the Intact Rat Heart when Administered before and after a Simulated Ischemic Insult-- Having shown protective effects of UCN on simulated hypoxic/ischemic reoxygenated cardiac myocytes in vitro, we next examined whether UCN had similar protective actions on the ischemic/reperfused isolated heart ex vivo (Fig. 3). In these experiments, UCN protected the isolated rat heart from 35 min of regional ischemia/2 h of reperfusion when added 30 min prior to the stress, as the percent of infarct size/risk zone decreased from 45.67 to 20.58% (p < 0.00001). Moreover, the addition of UCN for 30 min at reperfusion after the 35-min ischemic period reduced the percent infarct size/risk zone to 32.24% (p < 0.02). No significant hemodynamic changes in parameters such as heart rate, left ventricular developed pressure, and coronary flow with UCN were observed compared with the control untreated hearts. This study demonstrates that UCN results in a significant reduction in infarct size when administered either 30 min prior to ischemia or from the moment of reperfusion.

View larger version (36K): [in this window] [in a new window]   Fig. 3.   UCN reduces infarct size of the intact rat heart when administered before and after a simulated ischemic insult, as described under "Materials and Methods." UCN protected the isolated rat heart from 35 min of regional ischemia/2 h of reperfusion when added 30 min prior to the stress, as the percent infarct size/risk zone (IR) decreased from 45.67% (n = 8) to 20.58% (n = 7; ***, p < 0.00001). Moreover, the addition of UCN for 30 min after the 35-min ischemic period at reperfusion reduced the percent infarct size/risk zone to 32.24% (n = 8; *, p < 0.02 by Student's t test; *, p < 0.05 by ANOVA).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Cardiac muscle survival is of critical importance in maintaining the normal function of the heart. Adult cardiac muscle cells are terminally differentiated and have lost their ability to proliferate. Therefore, irreversible cardiac injury, e.g. following ischemia, results in scarring and eventual decrease in cardiac function. Identification of natural cardioprotective agents and the signaling pathways through which their cardioprotective effects are mediated is critical for the elucidation of the molecular basis of cardiac myocyte loss and rescue.

In this study, we have extended our previous observations on the cardioprotective properties of UCN. In in vitro cultures of primary rat cardiac myocytes exposed to simulated hypoxia/ischemia followed by reoxygenation, exogenous UCN reduces cardiac myocyte cell death when added after the simulated hypoxia/ischemia and during the reoxygenation/reperfusion period as well as when added prior to the simulated hypoxia/ischemia (20). Moreover, in the ischemic/reperfused isolated heart ex vivo, UCN is also cardioprotective when added to the perfusate after ischemia and during reperfusion. Since clinical intervention is possible only after the acute ischemic episode, the data suggest that UCN and derivatives thereof may have a role in the management of human myocardial infarction.

We have previously shown that UCN mRNA is expressed by both cultured neonatal rat cardiac myocytes and the adult rat heart, and not CRF, and that UCN transcripts are increased following simulated hypoxia/ischemia (20). By Western blotting, we have also demonstrated the presence of the 22-kDa UCN precursor protein in cardiac myocytes (data not shown) and that the mature 40-amino acid UCN peptide is released into the supernatant of cardiac myocytes exposed to simulated hypoxia/ischemia. This is consistent with the cardioprotective effects of these supernatants being inhibited by CRF-(9-41), a receptor antagonist of all CRF family members at both CRF-R1 and CRF-R2, and suggests that endogenous cardiac UCN is released from ischemic cardiac myocytes and exerts an autocrine/paracrine protective effect through cardiac CRF-R2. We have also shown that UCN protects cardiac myocytes from ceramide-induced apoptosis.² There is increasing evidence that UCN and CRF peptides are involved in cell survival mechanisms of a number of cells. CRF administered to hypoxic rat brain slices results in neuroprotection when administered during the hypoxic episode (42). The mechanism of action appears to be a direct neuronal effect. Therefore, we suggest that UCN peptide release may serve as a mechanism to protect cells from hypoxia/ischemia-induced cell death.

A number of studies have addressed which signaling and transactivating pathways are activated by ischemia and ischemia/reperfusion. In the heart, the p38 MAPKs and JNKs are induced by ischemia and ischemia/reperfusion (43-45, 47-49). The JNK and p38 stress-activated pathways have been linked to an increase in cell death in ischemic and reoxygenated cardiac cells (49). UCN failed to stimulate the phosphorylation and activation of both p38 and JNK. A highly specific inhibitor of p38 MAPK (SB203580) failed to inhibit the cardioprotective effect of UCN in all experiments (data not shown). Our experiments show that UCN induces ERK1/2-p42/44 phosphorylation and that inhibition of MEK1/2, the upstream activator of these enzymes, inhibits the cardioprotective effect of UCN. The target cardioprotective genes or the post-translational events induced by UCN-mediated activation of ERK1/2-p42/44 are unknown. However, in other cells, ERK1 and ERK2 (p42/44) have been associated with the increased expression of FLICE (FADD-like interleukin 1b-converting enzyme) like inhibitory protein, an inhibitor of the caspase cascade (50). Whether UCN mediates its cardioprotection by increasing the levels of FLICE-like inhibitory protein has yet to be determined.

It is known that both hypoxia/ischemia and reoxygenation impose redox stress on cardiac tissue. Although coronary reperfusion itself results in tissue injury (51), it is the only means of limiting infarct size, provided that it occurs early after coronary occlusion. In this study, we report for the first time that UCN reduces damage to an intact rat heart exposed to regional ischemia when given at reperfusion, which would be essential in the clinical setting. Growth factors such as insulin have been shown to exert anti-apoptotic effects in these cells when administered during reperfusion. Insulin-like growth factor I (52) and insulin (53) have been shown to inhibit apoptosis and necrosis in cardiac myocytes. Both insulin-like growth factor I and insulin act through phosphatidylinositol 3-kinase and receptor tyrosine kinases as well as the MEK1-ERK1/2-p42/44 signaling cascade (54). The benefit of UCN over these and other drugs will need to be investigated in the intact animal and human tissue.

Some cardioprotective factors such as CT-1 (55) and angiotensin II and vasopressin (56) are also potent inducers of hypertrophy. Hypertrophy is an adaptive response found in patients with ischemic and non-ischemic heart disease and results in molecular adaptations of both coronary vasculature and cardiac muscle. Initially, these responses to cardiac overload help to maintain cardiac output. However, prolonged hypertrophy eventually leads to cardiac failure (57). The hypertrophic response due to CT-1 is mediated by activation of Janus kinases with phosphorylation of STAT-1 and STAT-3 (55). The Janus kinase-STAT pathway has been implicated in hypertrophic responses of the heart (58); however, studies conducted in our laboratory failed to detect STAT-1 or STAT-3 tyrosine phosphorylation in cardiac myocytes induced by UCN or any increase in cardiac myocyte cell size using crystal violet staining.³ These studies suggest that UCN, unlike CT-1, is a cardioprotective agent that does not induce a hypertrophic response. Moreover, although 100 µg of UCN administered to sheep produced changes in cardiac function (18), no hemodynamic changes were observed in response to the lower doses of UCN used in the isolated rat hearts used in these experiments. A previous study on rats revealed that a subcutaneous injection of UCN caused a significant decrease in mean arterial blood pressure; hence, it acts as a hypotensive agent (59). Whether this finding will hinder its use as a therapeutic drug is not known, but will be addressed in future in in vivo models of cardiac failure.

The recent availability of reliable and specific assays for the UCN peptide will enable accurate measurement of UCN release and expression in our models of hypoxic/ischemic and hypoxic/ischemic/reperfusion injury and in future human studies (46). It is already clear, however, that as well as the adaptive role in the response to external stressors, UCN is also an important mediator of the response to stress at the level of the cell. We believe that these results establish a new and potentially clinically important role for UCN in protection from cellular stress, in addition to the well known function of the CRF family of peptides in integrating the complex response to external physical and psychological stresses. The use of these peptides in salvaging neurons and other cell types that express CRF receptors, in addition to cardiac myocytes, from cell death induced by cellular stressors warrants further investigation.

	FOOTNOTES

^* This work was supported by the British Heart Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence should be addressed. Tel.: 44-171-5049207; Fax: 44-171-3873310.

Present address; Dept. of Medical Physiology, Inst. of Medical Biology, University of Tromso, Tromso, Norway.

² B. K. Brar, A. K. Jonassen, A. Stephanou, G. Santilli, J. Railson, R. A. Knight, D. M. Yellon, and D. S. Latchman, unpublished observations.

³ B. K. Brar and J. Railson, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: UCN, urocortin; CRF, corticotrophin-releasing factor; CRF-R, corticotrophin-releasing factor receptor; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; FLICE, FADD-like interleukin 1b-converting enzyme; MEK, MAPK/ERK kinase; CT-1, cardiotrophin-1; JNK, c-Jun N-terminal kinase; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; FACS, fluorescence-activated cell sorting; ANOVA, one-way analysis of variance; STAT, signal transducer and activator of transcription.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]

				Y. Sztainberg, Y. Kuperman, O. Issler, S. Gil, J. Vaughan, J. Rivier, W. Vale, and A. Chen A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease FASEB J, July 1, 2009; 23(7): 2186 - 2196. [Abstract] [Full Text] [PDF]

				E. Calderon-Sanchez, C. Delgado, G. Ruiz-Hurtado, A. Dominguez-Rodriguez, V. Cachofeiro, M. Rodriguez-Moyano, A. M. Gomez, A. Ordonez, and T. Smani Urocortin induces positive inotropic effect in rat heart Cardiovasc Res, June 13, 2009; (2009) cvp161v2. [Abstract] [Full Text] [PDF]

				M. Huang, D. Kempuraj, N. Papadopoulou, T. Kourelis, J. Donelan, A. Manola, and T. C Theoharides Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-{kappa}B activation J. Mol. Endocrinol., May 1, 2009; 42(5): 397 - 405. [Abstract] [Full Text] [PDF]

				S. M. Soond, P. A. Townsend, S. P. Barry, R. A. Knight, D. S. Latchman, and A. Stephanou ERK and the F-box Protein {beta}TRCP Target STAT1 for Degradation J. Biol. Chem., June 6, 2008; 283(23): 16077 - 16083. [Abstract] [Full Text] [PDF]

				V. Champattanachai, R. B. Marchase, and J. C. Chatham Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2 Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1509 - C1520. [Abstract] [Full Text] [PDF]

				M. E. Davis, C. J. Pemberton, T. G. Yandle, S. F. Fisher, J. G. Lainchbury, C. M. Frampton, M. T. Rademaker, and M. Richards Urocortin 2 infusion in human heart failure Eur. Heart J., November 1, 2007; 28(21): 2589 - 2597. [Abstract] [Full Text] [PDF]

				J. Xu, F. Xu, J. D. Hennebold, T. A. Molskness, and R. L. Stouffer Expression and Role of the Corticotropin-Releasing Hormone/Urocortin-Receptor-Binding Protein System in the Primate Corpus Luteum during the Menstrual Cycle Endocrinology, November 1, 2007; 148(11): 5385 - 5395. [Abstract] [Full Text] [PDF]

				P. A. Townsend, S. M. Davidson, S. J. Clarke, I. Khaliulin, C. J. Carroll, T. M. Scarabelli, R. A. Knight, A. Stephanou, D. S. Latchman, and A. P. Halestrap Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H928 - H938. [Abstract] [Full Text] [PDF]

				S. V. Wu, P.-q. Yuan, L. Wang, Y. L. Peng, C.-Y. Chen, and Y. Tache Identification and Characterization of Multiple Corticotropin-Releasing Factor Type 2 Receptor Isoforms in the Rat Esophagus Endocrinology, April 1, 2007; 148(4): 1675 - 1687. [Abstract] [Full Text] [PDF]

				J.-X. Chen, H. Zeng, Q.-H. Tuo, H. Yu, B. Meyrick, and J. L. Aschner NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1664 - H1674. [Abstract] [Full Text] [PDF]

				M. E. Davis, C. J. Pemberton, T. G. Yandle, S. F. Fisher, J. G. Lainchbury, C. M. Frampton, M. T. Rademaker, and A. M. Richards Urocortin 2 Infusion in Healthy Humans: Hemodynamic, Neurohormonal, and Renal Responses J. Am. Coll. Cardiol., January 30, 2007; 49(4): 461 - 471. [Abstract] [Full Text] [PDF]

				A. Punn, M. A. Levine, and D. K. Grammatopoulos Identification of Signaling Molecules Mediating Corticotropin-Releasing Hormone-R1{alpha}-Mitogen-Activated Protein Kinase (MAPK) Interactions: The Critical Role of Phosphatidylinositol 3-Kinase in Regulating ERK1/2 But Not p38 MAPK Activation Mol. Endocrinol., December 1, 2006; 20(12): 3179 - 3195. [Abstract] [Full Text] [PDF]

				G. C. Boorse, C. A. Kholdani, A. F. Seasholtz, and R. J. Denver Corticotropin-Releasing Factor Is Cytoprotective in Xenopus Tadpole Tail: Coordination of Ligand, Receptor, and Binding Protein in Tail Muscle Cell Survival Endocrinology, March 1, 2006; 147(3): 1498 - 1507. [Abstract] [Full Text] [PDF]

				A. Chen, M. Perrin, B. Brar, C. Li, P. Jamieson, M. DiGruccio, K. Lewis, and W. Vale Mouse Corticotropin-Releasing Factor Receptor Type 2{alpha} Gene: Isolation, Distribution, Pharmacological Characterization and Regulation by Stress and Glucocorticoids Mol. Endocrinol., February 1, 2005; 19(2): 441 - 458. [Abstract] [Full Text] [PDF]

				T. M. Scarabelli, E. Pasini, G. Ferrari, M. Ferrari, A. Stephanou, K. Lawrence, P. Townsend, C. Chen-Scarabelli, G. Gitti, L. Saravolatz, et al. Warm blood cardioplegic arrest induces mitochondrial-mediated cardiomyocyte apoptosis associated with increased urocortin expression in viable cells J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 364 - 371. [Abstract] [Full Text] [PDF]

				C. R. R. Grace, M. H. Perrin, M. R. DiGruccio, C. L. Miller, J. E. Rivier, W. W. Vale, and R. Riek NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor PNAS, August 31, 2004; 101(35): 12836 - 12841. [Abstract] [Full Text] [PDF]

				K. Takahashi, K. Totsune, O. Murakami, M. Saruta, M. Nakabayashi, T. Suzuki, H. Sasano, and S. Shibahara Expression of Urocortin III/Stresscopin in Human Heart and Kidney J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1897 - 1903. [Abstract] [Full Text] [PDF]

				B. K. Brar, A. Chen, M. H. Perrin, and W. Vale Specificity and Regulation of Extracellularly Regulated Kinase1/2 Phosphorylation through Corticotropin-Releasing Factor (CRF) Receptors 1 and 2{beta} by the CRF/Urocortin Family of Peptides Endocrinology, April 1, 2004; 145(4): 1718 - 1729. [Abstract] [Full Text] [PDF]

				T. L. Bale, M. Hoshijima, Y. Gu, N. Dalton, K. R. Anderson, K.-F. Lee, J. Rivier, K. R. Chien, W. W. Vale, and K. L. Peterson The cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure PNAS, March 9, 2004; 101(10): 3697 - 3702. [Abstract] [Full Text] [PDF]

				M. E. Davis, C. J. Pemberton, T. G. Yandle, J. G. Lainchbury, M. T. Rademaker, M. G. Nicholls, C. M. Frampton, and A. M. Richards Urocortin-1 Infusion in Normal Humans J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1402 - 1409. [Abstract] [Full Text] [PDF]

				N. Papadopoulou, J. Chen, H. S. Randeva, M. A. Levine, E. W. Hillhouse, and D. K. Grammatopoulos Protein Kinase A-Induced Negative Regulation of the Corticotropin-Releasing Hormone R1{alpha} Receptor-Extracellularly Regulated Kinase Signal Transduction Pathway: The Critical Role of Ser301 for Signaling Switch and Selectivity Mol. Endocrinol., March 1, 2004; 18(3): 624 - 639. [Abstract] [Full Text] [PDF]

				D. J Hausenloy and D. M Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc Res, February 15, 2004; 61(3): 448 - 460. [Abstract] [Full Text] [PDF]

				A. L. Garcia-Villalon, E. Sanz, L. Monge, N. Fernandez, B. Climent, and G. Dieguez Urocortin Protects Coronary Endothelial Function During Ischemia-Reperfusion: A Brief Communication Experimental Biology and Medicine, January 1, 2004; 229(1): 118 - 120. [Abstract] [Full Text] [PDF]

				B. K. Brar, A. K. Jonassen, E. M. Egorina, A. Chen, A. Negro, M. H. Perrin, O. D. Mjos, D. S. Latchman, K.-F. Lee, and W. Vale Urocortin-II and Urocortin-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for Corticotropin Releasing Factor Receptor Type 2 in the Murine Heart Endocrinology, January 1, 2004; 145(1): 24 - 35. [Abstract] [Full Text] [PDF]

				C. Li, P. Chen, J. Vaughan, A. Blount, A. Chen, P. M. Jamieson, J. Rivier, M. S. Smith, and W. Vale Urocortin III Is Expressed in Pancreatic {beta}-Cells and Stimulates Insulin and Glucagon Secretion Endocrinology, July 1, 2003; 144(7): 3216 - 3224. [Abstract] [Full Text] [PDF]

				M. H. Perrin, M. R. DiGruccio, S. C. Koerber, J. E. Rivier, K. S. Kunitake, D. L. Bain, W. H. Fischer, and W. W. Vale A Soluble Form of the First Extracellular Domain of Mouse Type 2beta Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity J. Biol. Chem., April 25, 2003; 278(18): 15595 - 15600. [Abstract] [Full Text] [PDF]

				Y. Huang, F. L. Chan, C.-W. Lau, S.-Y. Tsang, Z.-Y. Chen, G.-W. He, and X. Yao Roles of cyclic AMP and Ca2+-activated K+ channels in endothelium-independent relaxation by urocortin in the rat coronary artery Cardiovasc Res, March 1, 2003; 57(3): 824 - 833. [Abstract] [Full Text] [PDF]

				J. M. Gordon, G. J. Dusting, O. L. Woodman, and R. H. Ritchie Cardioprotective action of CRF peptide urocortin against simulated ischemia in adult rat cardiomyocytes Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H330 - H336. [Abstract] [Full Text] [PDF]

				D. Schulman, D. S. Latchman, and D. M. Yellon Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1481 - H1488. [Abstract] [Full Text] [PDF]

				K.M. Lawrence, A. Chanalaris, T. Scarabelli, M. Hubank, E. Pasini, P.A. Townsend, L. Comini, R. Ferrari, A. Tinker, A. Stephanou, et al. KATP Channel Gene Expression Is Induced by Urocortin and Mediates Its Cardioprotective Effect Circulation, September 17, 2002; 106(12): 1556 - 1562. [Abstract] [Full Text] [PDF]

				T. M. Scarabelli, E. Pasini, A. Stephanou, L. Comini, S. Curello, R. Raddino, R. Ferrari, R. Knight, and D. S. Latchman urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion J. Am. Coll. Cardiol., July 3, 2002; 40(1): 155 - 161. [Abstract] [Full Text] [PDF]

				E. Dermitzaki, C. Tsatsanis, A. Gravanis, and A. N. Margioris Corticotropin-releasing Hormone Induces Fas Ligand Production and Apoptosis in PC12 Cells via Activation of p38 Mitogen-activated Protein Kinase J. Biol. Chem., March 29, 2002; 277(14): 12280 - 12287. [Abstract] [Full Text] [PDF]

				W. A. Pedersen, R. Wan, P. Zhang, and M. P. Mattson Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons from Oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I J. Neurosci., January 15, 2002; 22(2): 404 - 412. [Abstract] [Full Text] [PDF]

				Y. Kimura, K. Takahashi, K. Totsune, Y. Muramatsu, C. Kaneko, A. D. Darnel, T. Suzuki, M. Ebina, T. Nukiwa, and H. Sasano Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 340 - 346. [Abstract] [Full Text] [PDF]

				L. Wang, V. Martinez, J. E. Rivier, and Y. Tache Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2 Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2001; 281(5): R1401 - R1410. [Abstract] [Full Text] [PDF]

				M. Kohno, Y. Kawahito, Y. Tsubouchi, A. Hashiramoto, R. Yamada, K.-i. Inoue, Y. Kusaka, T. Kubo, I. J. Elenkov, G. P. Chrousos, et al. Urocortin Expression in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis: Relation to Inflammatory Activity J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4344 - 4352. [Abstract] [Full Text] [PDF]

				B. A. Ballif and J. Blenis Molecular Mechanisms Mediating Mammalian Mitogen-activated Protein Kinase (MAPK) Kinase (MEK)-MAPK Cell Survival Signals Cell Growth Differ., August 1, 2001; 12(8): 397 - 408. [Full Text] [PDF]

				A. SLOMINSKI, J. WORTSMAN, A. PISARCHIK, B. ZBYTEK, E. A. LINTON, J. E. MAZURKIEWICZ, and E. T. WEI Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors FASEB J, August 1, 2001; 15(10): 1678 - 1693. [Abstract] [Full Text] [PDF]

				B. K Brar, A. Stephanou, Z. Liao, R. M O'Leary, D. Pennica, D. M Yellon, and D. S Latchman Cardiotrophin-1 can protect cardiac myocytes from injury when added both prior to simulated ischaemia and at reoxygenation Cardiovasc Res, August 1, 2001; 51(2): 265 - 274. [Abstract] [Full Text] [PDF]

				D. K. Grammatopoulos, H. S. Randeva, M. A. Levine, E. S. Katsanou, and E. W. Hillhouse Urocortin, but Not Corticotropin-Releasing Hormone (CRH), Activates the Mitogen-Activated Protein Kinase Signal Transduction Pathway in Human Pregnant Myometrium: An Effect Mediated via R1{{alpha}} and R2{beta} CRH Receptor Subtypes and Stimulation of Gq-Proteins Mol. Endocrinol., December 1, 2000; 14(12): 2076 - 2091. [Abstract] [Full Text]

				A. Stephanou, T. M. Scarabelli, B. K. Brar, Y. Nakanishi, M. Matsumura, R. A. Knight, and D. S. Latchman Induction of Apoptosis and Fas Receptor/Fas Ligand Expression by Ischemia/Reperfusion in Cardiac Myocytes Requires Serine 727 of the STAT-1 Transcription Factor but Not Tyrosine 701 J. Biol. Chem., July 20, 2001; 276(30): 28340 - 28347. [Abstract] [Full Text] [PDF]

				R. Gusterson, B. Brar, D. Faulkes, A. Giordano, J. Chrivia, and D. Latchman The Transcriptional Co-activators CBP and p300 Are Activated via Phenylephrine through the p42/p44 MAPK Cascade J. Biol. Chem., January 18, 2002; 277(4): 2517 - 2524. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brar, B. K. Articles by Latchman, D. S. Search for Related Content PubMed PubMed Citation Articles by Brar, B. K. Articles by Latchman, D. S. Social Bookmarking                      What's this?